Burke Robinson
Alpharetta, GANPI 1316949597
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $448,295 of the $501,596 with a category attached, or 89.4%. Galderma Laboratories, L.p. accounts for 99.9% of it on its own, with 3 other manufacturers making up the rest.
Across 433 payments — averaging $1158.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Galderma Laboratories, L.p.$501K
- AbbVie$336
- Zimmer Biomet$123
- Merz North America, Inc.$95
What the payments were for
- Consulting fees$11,0502%
- Speaking & faculty fees$448,29589%
- Travel & lodging$33,9217%
- Food & beverage$8,3302%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Galderma Laboratories, L.p. | 417 | $501,041 |
| AbbVie(2 entities) | 14 | $336 |
| Zimmer Biomet | 1 | $123 |
| Merz North America, Inc. | 1 | $95 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 28 | $1,092 |
| CefuroximeCefuroxime Axetil | 57 | $499 |
| Ondansetron OdtOndansetron | 40 | $437 |
| Methylprednisolone | 50 | $197 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 46 | $182 |
| ValacyclovirValacyclovir Hcl | 15 | $141 |
| Trazodone Hcl | 46 | $44 |
Paid to pharmacies, not to this prescriber.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.